Cyprium Therapeutics, A Fortress Biotech Subsidiary Company, Completes Asset Transfer Of CUTX-101 Copper Histidinate Product Candidate For Treatment Of Menkes Disease, To Sentynl Therapeutics, A Wholly-Owned Subsidiary Of Zydus Lifesciences Ltd.
Benzinga Newsdesk - Dec 6, 2023, 8:41AM